A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission

Steven J. O'Day, Susan N. Rabinowe, Donna Neuberg, Arnold S. Freedman, Robert J. Soiffer, Neil A. Spector, Michael Robertson, Kenneth Anderson, Mary Whelan, Kelly Pesek, Jerome Ritz, Lee M. Nadler

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) clearly hastens myeloid recovery in patients with relapsed hematologic malignancies undergoing autologous bone marrow transplantation (ABMT). In efforts to further improve neutrophil engraftment and shorten hospital stay in ABMT patients, rhGM-CSF was administered by a potentially more potent route (continuous infusion) to non-Hodgkin's lymphoma (NHL) patients with better BM reserve (first remission). Time to myeloid engraftment was compared with that of NHL patients treated in first remission at our institution on a similar ABMT protocol but without growth factor support (controls). Median neutrophil engraftment (absolute neutrophil count, 500 cells/μL) in first remission patients treated with rhGM-CSF was 14 days, compared with 22 days in controls (P = .0001). Hospital stays were also significantly reduced for rhGM-CSF patients (P = .0003). Platelet engraftment did not differ between the two groups. Persistent fever and generalized serositis were the primary toxicities. rhGM-CSF, delivered by this route, was efficacious but more toxic than 2-hour rhGM-CSF infusions previously reported by other investigators. Future alterations in both dose and schedule may retain comparable efficacy yet diminish toxicity.

Original languageEnglish (US)
Pages (from-to)2707-2714
Number of pages8
JournalBlood
Volume83
Issue number9
StatePublished - May 1 1994
Externally publishedYes

Fingerprint

Autologous Transplantation
Granulocyte-Macrophage Colony-Stimulating Factor
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Bone
Neutrophils
Toxicity
Length of Stay
Serositis
Poisons
Hematologic Neoplasms
Platelets
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Fever
Blood Platelets
Cell Count
Research Personnel
Recovery

ASJC Scopus subject areas

  • Hematology

Cite this

A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. / O'Day, Steven J.; Rabinowe, Susan N.; Neuberg, Donna; Freedman, Arnold S.; Soiffer, Robert J.; Spector, Neil A.; Robertson, Michael; Anderson, Kenneth; Whelan, Mary; Pesek, Kelly; Ritz, Jerome; Nadler, Lee M.

In: Blood, Vol. 83, No. 9, 01.05.1994, p. 2707-2714.

Research output: Contribution to journalArticle

O'Day, SJ, Rabinowe, SN, Neuberg, D, Freedman, AS, Soiffer, RJ, Spector, NA, Robertson, M, Anderson, K, Whelan, M, Pesek, K, Ritz, J & Nadler, LM 1994, 'A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission', Blood, vol. 83, no. 9, pp. 2707-2714.
O'Day, Steven J. ; Rabinowe, Susan N. ; Neuberg, Donna ; Freedman, Arnold S. ; Soiffer, Robert J. ; Spector, Neil A. ; Robertson, Michael ; Anderson, Kenneth ; Whelan, Mary ; Pesek, Kelly ; Ritz, Jerome ; Nadler, Lee M. / A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. In: Blood. 1994 ; Vol. 83, No. 9. pp. 2707-2714.
@article{bb315609dcfb461fb8be98404c83cfbb,
title = "A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission",
abstract = "Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) clearly hastens myeloid recovery in patients with relapsed hematologic malignancies undergoing autologous bone marrow transplantation (ABMT). In efforts to further improve neutrophil engraftment and shorten hospital stay in ABMT patients, rhGM-CSF was administered by a potentially more potent route (continuous infusion) to non-Hodgkin's lymphoma (NHL) patients with better BM reserve (first remission). Time to myeloid engraftment was compared with that of NHL patients treated in first remission at our institution on a similar ABMT protocol but without growth factor support (controls). Median neutrophil engraftment (absolute neutrophil count, 500 cells/μL) in first remission patients treated with rhGM-CSF was 14 days, compared with 22 days in controls (P = .0001). Hospital stays were also significantly reduced for rhGM-CSF patients (P = .0003). Platelet engraftment did not differ between the two groups. Persistent fever and generalized serositis were the primary toxicities. rhGM-CSF, delivered by this route, was efficacious but more toxic than 2-hour rhGM-CSF infusions previously reported by other investigators. Future alterations in both dose and schedule may retain comparable efficacy yet diminish toxicity.",
author = "O'Day, {Steven J.} and Rabinowe, {Susan N.} and Donna Neuberg and Freedman, {Arnold S.} and Soiffer, {Robert J.} and Spector, {Neil A.} and Michael Robertson and Kenneth Anderson and Mary Whelan and Kelly Pesek and Jerome Ritz and Nadler, {Lee M.}",
year = "1994",
month = "5",
day = "1",
language = "English (US)",
volume = "83",
pages = "2707--2714",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission

AU - O'Day, Steven J.

AU - Rabinowe, Susan N.

AU - Neuberg, Donna

AU - Freedman, Arnold S.

AU - Soiffer, Robert J.

AU - Spector, Neil A.

AU - Robertson, Michael

AU - Anderson, Kenneth

AU - Whelan, Mary

AU - Pesek, Kelly

AU - Ritz, Jerome

AU - Nadler, Lee M.

PY - 1994/5/1

Y1 - 1994/5/1

N2 - Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) clearly hastens myeloid recovery in patients with relapsed hematologic malignancies undergoing autologous bone marrow transplantation (ABMT). In efforts to further improve neutrophil engraftment and shorten hospital stay in ABMT patients, rhGM-CSF was administered by a potentially more potent route (continuous infusion) to non-Hodgkin's lymphoma (NHL) patients with better BM reserve (first remission). Time to myeloid engraftment was compared with that of NHL patients treated in first remission at our institution on a similar ABMT protocol but without growth factor support (controls). Median neutrophil engraftment (absolute neutrophil count, 500 cells/μL) in first remission patients treated with rhGM-CSF was 14 days, compared with 22 days in controls (P = .0001). Hospital stays were also significantly reduced for rhGM-CSF patients (P = .0003). Platelet engraftment did not differ between the two groups. Persistent fever and generalized serositis were the primary toxicities. rhGM-CSF, delivered by this route, was efficacious but more toxic than 2-hour rhGM-CSF infusions previously reported by other investigators. Future alterations in both dose and schedule may retain comparable efficacy yet diminish toxicity.

AB - Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) clearly hastens myeloid recovery in patients with relapsed hematologic malignancies undergoing autologous bone marrow transplantation (ABMT). In efforts to further improve neutrophil engraftment and shorten hospital stay in ABMT patients, rhGM-CSF was administered by a potentially more potent route (continuous infusion) to non-Hodgkin's lymphoma (NHL) patients with better BM reserve (first remission). Time to myeloid engraftment was compared with that of NHL patients treated in first remission at our institution on a similar ABMT protocol but without growth factor support (controls). Median neutrophil engraftment (absolute neutrophil count, 500 cells/μL) in first remission patients treated with rhGM-CSF was 14 days, compared with 22 days in controls (P = .0001). Hospital stays were also significantly reduced for rhGM-CSF patients (P = .0003). Platelet engraftment did not differ between the two groups. Persistent fever and generalized serositis were the primary toxicities. rhGM-CSF, delivered by this route, was efficacious but more toxic than 2-hour rhGM-CSF infusions previously reported by other investigators. Future alterations in both dose and schedule may retain comparable efficacy yet diminish toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0028328796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028328796&partnerID=8YFLogxK

M3 - Article

C2 - 8167349

AN - SCOPUS:0028328796

VL - 83

SP - 2707

EP - 2714

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -